Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.

Plasmid DNA (pDNA) is a fundamental starting material for therapeutic development, including for viral vectors, mRNA therapies, and DNA vaccines. Researchers use capture methods such as anion exchange ...

Plasmids, small circular DNA molecules found in bacteria, may contain antibiotic-resistance genes and have the ability to replicate independently. Bacteria can transfer these plasmids to one another, ...

Are plasmid DNA issues impacting your mRNA program delivery? Many biotech and pharma companies focused on advanced therapy manufacturing are experiencing challenges associated with their pDNA supply, ...

As cell and gene therapies, mRNA vaccines and other cutting-edge meds come into their own, developers have put a strain on the industry's supply chain. That’s where biopharma building block outfits ...

Nucleic acid purification procedures have enjoyed a long history, beginning with the first isolation of "nuclein" in 1869 by Freidrich Meischer. In 1958, Matthew Meselson and Frank Stahl demonstrated ...

DNA-based information is a new field hoping to fill the gap in long-term data storage by using DNA as an information storage medium. Despite DNA’s potential, researchers face problems accurately ...